Executive record

Janet Hammond, M.D., Ph.D.

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:janet-hammond-m-d-ph-d-avirVersion: public-0As of: 2026-09-30

Not yet claimed9 published Claims2 sources

Key Claims

Biography

Has served as Chief Development Officer since August 2020. Previously served as VP and Therapeutic Area Head for General Medicine and Infectious Disease Development at AbbVie, Inc. and SVP Global Head of Infectious Diseases at F. Hoffmann-La Roche.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2026 to end not publishedExecutive title: Chief Development Officer · Organization not publishedAVIR 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. AVIR 10-K executive officers

    sec filing · Source published: Mar 5, 2026 · Retrieved: May 14, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 14, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 14, 2026
    • Executive company: Executive at Atea Pharmaceuticals, Inc. · Claim reviewed: May 14, 2026
    • Executive title: Executive title: Chief Development Officer · Claim reviewed: May 14, 2026
    • Other Company Role: Janet Hammond, M.D., Ph.D. is also linked to Enterprise Therapeutics Ltd. as board of directors member. · Claim reviewed: May 14, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 14, 2026

  2. AVIR executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise reported in filings · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Atea Pharmaceuticals, Inc. · Claim reviewed: May 14, 2026
    • Executive function: Other Executive (OTHER_EXECUTIVE) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Development Officer · Claim reviewed: May 14, 2026